Date Title Description PDF
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
27 Apr 2016 Información sobre resultados (2) The Company releases the press release related to the 2016 first quarter results Download
27 Apr 2016 Información sobre resultados The Company releases the press release related to the 2016 first quarter results Download
27 Apr 2016 Convocatorias y Acuerdos de Juntas y Asambleas Generales ROVI informs about the call for the General Shareholders Meeting Download
04 Apr 2016 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2016 - correction Download
01 Apr 2016 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2016 Download

Pages